Inflammation is the first line of defense against pathogens. The innate immune system provides an early mechanism of host protection by producing type I interferons (IFN), complement proteins, and chemokines/cytokines to limit viral infection [
79,
80]. While a robust innate immune response is necessary to elicit protective adaptive immunity, a prolonged and/or overactive immune response contributes toward pathological tissue injury [
81]. Interestingly, pre-clinical studies showed that excess cytokine release after SARS-CoV infection dampened adaptive immunity [
82]. In line with this observation, despite an increase in leukocyte activation and massive release of pro-inflammatory cytokines, SARS-CoV-2 infection is associated with lymphopenia, including suppression of both CD4
+ and CD8
+ T cells as well as the increased appearance of exhausted T cells [
83‐
85]. Given this progression, significant attention has been focused on the development of a “cytokine storm,” the rapid pathological release of excess cytokines, which is associated with high fever, respiratory distress, multi-organ failure, and increased mortality over the first 2 weeks in COVID-19 patients [
86].
Cytokine storm
Critically ill COVID-19 patients exhibited an increased ratio of white blood cells/lymphocytes and higher plasma levels of C-reactive protein (CRP), IL-2, IL-7, IL-10, GSCF, IP10 (CXCL10), MCP-1 (CCL2), MIP-1α (CCL3), and TNF-α, as compared to non-ICU patients [
9,
87]. Inflammatory cytokines, such as IL-6, IL-10, and TNF-α, are elevated following infection with SARS-CoV-2 and are believed to orchestrate a cytokine storm [
84]. Given these appreciated detrimental effects, a number of clinical trials using tocilizumab, an IL-6 receptor antagonist (NCT04306705, NCT04322773); sarilumab, a IL-6 receptor antagonist (NCT04322773, NCT04315298); or clazakizumab, an IL-6 neutralizing antibody (NCT04343989; NCT04348500), were initiated as potential therapies to limit the cytokine storm in COVID-19 patients.
In contrast to the established association between the cytokine storm and respiratory distress in COVID-19 patients, relatively less is known about the lasting neurological effects of these events. The CNS is regarded as an immune-privileged organ, yet the brain is highly vulnerable to inflammatory mediators and tissue hypoxia [
88‐
91]. Infectious encephalitis is an inflammation of the brain that may develop in bacteria- or virus-infected children, elderly, and immuno-compromised individuals. While mild encephalitis produces transient flu-like symptoms, including fever, headache, seizures, light sensitivity, neck stiffness, and loss of consciousness, more severe cases can produce confusion, psychosis, limb weakness, double vision, cognitive impairments, speech and hearing deficits, coma, and increased fatality. During the course of COVID-19 infection, reports of a rare condition, acute necrotizing hemorrhagic encephalopathy, emerged in patients showing intracranial cytokine storm syndrome without direct viral invasion [
92]. Radiological imaging of acute necrotizing hemorrhagic encephalopathy indicates lesions within the thalamus, brain stem, and cerebral white matter [
93], suggesting the likely need for neurological assessments of COVID-19 patients. In addition, cytokine-induced pulmonary injury during ARDS may adversely affect brain function due to the intimate association between the lungs and the respiratory centers in the medulla and pons of the brain stem [
94‐
97]. Thus, the neurological manifestations of COVID-19 may be secondary to the consequences of ARDS-mediated inflammation and hypoxemia/hypoxia [
94,
95]. As clinical data becomes more widely available regarding the link between the nervous and respiratory systems, this knowledge will greatly shape further pre-clinical efforts.
Immunomodulatory therapies to manage the neurological complications from SARS-CoV-2
Understanding the immune dysregulation in patients with COVID-19 will provide a greater understanding of SARS-CoV-2 pathogenesis. The detrimental impact of unrestrained immune activation and the cytokine storm are clearly evident, but therapeutic targets beyond anti-viral drugs remain a major obstacle to limiting neurological injury secondary to COVID-19. As a significant member of the pattern recognition receptor (PRR) family, Toll-like receptors (TLRs) play a crucial role in the initiation of immune responses against viral infections. In addition to initiating the intracellular response to viral RNA, TLRs induce signaling cascades and activate transcription factors that shape the cellular response to infection. Along these lines, activation of TLRs mobilize and recruit innate immune cells (e.g., neutrophils, monocytes, innate lymphoid cells) and induce cytokines and chemokines that limit viral progression and activate acquired immunity [
98]. Of the TLRs, TLR3, which is expressed in both immune and non-immune cells, recognizes double-stranded RNA (CoVs are double-stranded RNA viruses). Upon activation, TLR3 induces interferon regulatory transcription factor 3 (IRF3) to stimulate the production of type I interferons as a host defense mechanism against viruses [
99]. Importantly, mounting evidence suggests that TLR3 may initiate the cytokine storm and drive systemic inflammatory responses [
100‐
102]. Thus, TLR3 may represent a target for immunotherapeutic modulation to limit neurological dysfunction in COVID-19 patients [
103].
Do coagulopathies contribute to the neurological consequences of COVID-19?
COVID-19 patients frequently exhibit complications associated with coagulopathy, including venous thromboembolism, acute coronary syndrome, myocardial infarction, and cerebral infarction [
104‐
107]. SARS-CoV-2 infection was associated with prolonged prothrombin time, platelet abnormalities, elevated levels of D-dimer, increased fibrinogen/fibrin degradation products, and sepsis-induced coagulopathy (SIC), a form of disseminated intravascular coagulation (DIC), which was observed in the majority of COVID-19-related deaths [
108,
109]. Severe COVID-19 patients exhibit hypoxia, a risk factor that increases thrombosis via activation of hypoxia-inducible transcriptional regulation and by increasing blood viscosity [
110]. Given the role of coagulopathy, administration of anticoagulants were postulated as a treatment for severe COVID-19 patients [
106,
109]; however, anticoagulation did not reduce life-threatening thrombotic complications in a recent multi-center prospective cohort study of 150 COVID-19 patients with ARDS [
105], suggesting the need for extensive research to identify alternative targets for therapeutic intervention.
With respect to the CNS, cytokine release, encephalopathy, and onset of ischemic stroke symptoms are correlated in COVID-19 patients [
111,
112]. Inflammation and coagulation are inextricably linked processes that exhibit reciprocal cross-talk [
113]. Systemic inflammation activates coagulation mechanisms by driving tissue factor-mediated thrombin generation and inhibiting endogenous fibrinolysis. In turn, activation of the coagulation system may influence inflammatory activity and contribute toward the development of hemorrhagic fever and thrombotic microangiopathy. While a clear association exists between SARS-CoV-2 and stroke incidence, it remains unanswered whether coagulation, secondary to COVID-19 infection, is an initiating factor for ischemic stroke or whether the immune response in response to the viral infection worsens the severity of a stroke. In support of the former possibility, elevated inflammation may heighten the risk of developing an acute ischemic stroke in the elderly, potentially via modulation of the coagulation cascade, whereas the latter possibility may be explained by exacerbation of the post-stroke inflammatory response [
114‐
117]. While it is clear that COVID-19 patients exhibiting pro-thrombotic and/or pro-inflammatory activation may require neurological evaluation, further clinical data and pre-clinical research are needed to define the mechanistic link between SARS-CoV-2 and stroke outcomes.
Given the limited efficacy of broad anticoagulants in COVID-19 patients, alternative therapeutic targets are needed to reduce the detrimental effects of coagulopathies. Neutrophils are circulating innate immune cells that rapidly mobilize to phagocytose pathogens as a mechanism of host protection after an infection. An elevated neutrophil-to-lymphocyte ratio was an independent risk factor for mortality in hospitalized COVID-19 patients [
118‐
120]. Recent evidence suggests that activated neutrophils also may extrude a meshwork of chromatin fibers into the extracellular space to form cloud-like neutrophil extracellular traps (NETs), which may function as a mechanism of pathogen trapping. Extensive infiltration of neutrophils into the pulmonary capillaries of COVID-19 patients was associated with fibrin deposition and vascular lesions in the absence of sepsis while elevated neutrophil counts were associated with ocular dysfunction during SARS-CoV-2 infection [
121‐
125]. Moreover, NETs, which stimulate pro-inflammatory responses in human airway epithelial cells [
126], are present in many pulmonary diseases, including asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, respiratory syncytial virus bronchiolitis, influenza infection, bacterial pneumonia, ARDS, and tuberculosis [
127‐
132]. While the extent of neutrophil priming and NET formation in ARDS patients correlated with disease severity and mortality [
130,
133‐
136], the clinical significance of NETs in the pathophysiology of COVID-19 remains undefined.
Sera from COVID-19 patients displayed elevated levels of cell-free DNA, myeloperoxidase-DNA complexes, and citrullinated histone H3, suggesting NET formation and raising the possibility that NETs may provide a potential target for intervention in COVID-19 patients [
121,
137]. Interestingly, in addition to roles in host defense against viruses and bacteria, NETs also provide a scaffold for thrombogenesis [
138,
139]. Indeed, impaired degradation of NETs is clinically associated with acute thrombotic microangiopathies [
140], while the presence of citrullinated histone H3, a biomarker of NET formation, within thrombi retrieved from acute ischemic stroke patients was independently associated with patient mortality [
141,
142]. Of interest, we recently reported that elevated NET formation was associated with microvascular occlusion and cerebral hypoperfusion after acute brain injury in both mice and humans [
143]. Conversely, administration of recombinant human DNase-I, an FDA-approved drug under investigation for the management of COVID-19-induced ARDS [
144], improved blood flow and outcomes after both experimental stroke and traumatic brain injury [
143,
145‐
147]. Thus, the widespread generation of NETs after SARS-CoV-2 may provide a potential target to reduce acute and chronic neurological consequences, including headache, elevated stroke risk, and potential cognitive issues due to COVID-19.